Adhesion molecules in scleroderma systematica

Cite item

Full Text


  1. Seilbold J. R. Connective tissue disease characterized by fibrosis. In: Keliey W. N.. Harris E. D., Ruddy S., Sledge С. В., eds. Textbook of rheumatology. Philadelphia: W. B. Saunders; 1993. 1113-1143.
  2. LeRoy E. С. A brief overview of the pathogenesis of scleroderma (systemic sclerosis). Ann. Rheum. Dis. 1992; 130: 1327- 1328.
  3. Kahaleh B. Lymphocyte interactions with the vascular endothelium in systemic sclerosis. Clin. Dernatol. 1994; 12: 361-367.
  4. Piela-Smith T. H., Korn J. H. Lymphocyte modulation of fibroblast function in systemic sclerosis. Ibid. 369-377.
  5. Mojcik С. F., Shevach E. M. Adhesion molecules. A rheumatologic perspective. Arthr. and Rheum. 1997; 40(6): 991-1004.
  6. Боценовский В. А., Барышников А. Ю. Молекулы клеточной адгезии человека. Успехи соврем, бол. 1994; 114(6): 741 - 753.
  7. Carlos Т. М., Harlan J. M. Leukocyte-endothelial adhesion molecules. Blood 1994; 84: 2068-2101.
  8. Smith E. A. Connective tissue metabolism including cytokines in scleroderma. Curr. Opin. Rheumatol. 1992; 4(6): 869-877.
  9. Bevilacqua M. P., Stengelin S., Gimbrone M. A., Seed B. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 1989; 243: 1160-1165.
  10. Springer T. A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. 1994; 76: 301 - 314.
  11. Hynes R. O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
  12. Hemler M. E. VLA proteins in the integrin family: structures, functions and their roles on leukocytes. Annu. Rev. Immunol. 1990; 8: 365-
  13. Springer T. A. Adhesion receptors of the immune system. Nature. 1990; 346: 425-434.
  14. Elices M. J., Osborn L., Takada Y. et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990; 60: 557-584.
  15. Straiten U. G, Lifka A., Gosslar U. et al. Distinct hiding specificities of integrins a4[37 (LPAM-1), a4(31 (VLA-4), and aIEL[37. Int. Immunol. 1994; 6: 263-275.
  16. Davenpeck К. L., Sterbinsky S. A., Bochner В. S. Rat neutrophils express a4 and pi integrins and bind to vascular cell adhesion molecule-1 (VCAM-1) and mucosal aggressin cell adhesion molecule-1 (MadCAM-1). Blood 1998; 91: 2341 - 2346.
  17. Ruoslahti E., Pierschbacher M. D. New perspectives in cell adhesion: RGD and integrins. Science 1987; 238: 491-497.
  18. Masumoto A., Hemler M. E. Multiple activation states of VLA4 mechanistic differences between adhesion to CSl/fibronectin and to vascular cell adgesion molecule-1. J. Biol. Chem. 1993; 268: 228-234.
  19. Buck C. A. Immunoglobulin superfamily: structure, function and relationship to other receptor molecules. Semin. Cell Biol. 1992; 3: 179-188.
  20. Sato S. Abnormalities of adhesion molecules and chemokines in scleroderma. Curr. Opin. Rheumatol. 1999; 1: 503-507.
  21. Pigott R., Dillon L. P., Hemingway J. H., Gearing A. J. Soluble forms of E-selectin, ICAM-I and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem. Biophys. Res. Commun. 1992; 187: 584-589.
  22. Kitani A., Nakashima N., Izumihara T. et al. Soluble VCAM-1 induces chemotaxis of Jurkat and synovial fluid T cells bearing high affinity very late antigen-4. J. Immunol. 1998; 161: 4931-4938.
  23. Butcher E. C. Leukocyte-endothelial recognition: three (or more) steps to specificity and diversity. Cell 1991; 67: 1033- 1036.
  24. Shimizu Y., van Seventer G. A., Morgan K. J., Shaw S. Regulated expression and binding of free VLA (pi) integrin receptors on T cells. Nature 1990; 345: 250-253.
  25. Watson S. R., Fennie C., Lasky L. A. Neutrophil influx into an inflammatory site inhibited by a soluble homing receptor-lgG chimaera. Ibid. 1991; 349: 164-167.
  26. Von Andrian U. H., Chambers J. D., McEvoy L. M. et al. Twostep model of leukocyte-endothelial cell interaction in inflammation: distinct roles for LECAM-1 and the leukocyte p2 integris in vivo. Proc. Natl. Acad. Sci. USA. 1991; 88: 75387542.
  27. Penning C. A., Cunnigham J., French M. A. H. et al. Antibody dependent cellular cytoxicity of human vascular, endothelium in systemic sclerosis. Clin. Exp. Immunol. 1984; 58: 548-552.
  28. Giacomelli R., Matucci-Cerinic M., Cipriani P. et al. Circulating Vdeltal + T cells are activated and accumulate in the skin of systemic sclerosis patients. Arthr. and Rheum. 1998; 41(2): 327-334.
  29. Rudnicka L., Majewski S., Skiendzielewska A. et al. Adhesion of peripheral blood mononuclear cells to vascular endothelium in patients with systemic sclerosis (scleroderma). Ibid. 1992; 35(7): 771-775.
  30. Delia Bella S., Molteni M., Mocellin С. et al. Lymphocyte-endothelium interaction in systemic sclerosis and Raynaud's phenomenon. Clin. Exp. Rheumatol. 2001; 19(6): 647-654.
  31. Becker H., Langrock A., Federlin K. Imbalance of CD4+ lymphocyte subsets in patients with mixed connective tissue disease. Clin. Exp. Immunol. 1992; 88(1): 91-95.
  32. White B. Immunopathogenesis of systemic sclerosis. Rheum. Dis. Clin. N. Am. 1996; 22(4): 695-708.
  33. Prescott R. J., Freemont A. J., Jones C. J. et al. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J. Pathol. 1992; 166: 225-263.
  34. Gruschwitz M. S., Vieth G. Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early stage. Artht. and Rheum. 1998; 40(3): 540-550.
  35. Denton C. P., Shi-Wen X., Sutton A. et al. Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin. Exp. Immunol. 1998; 114(2): 293-300.
  36. Luster A. D. Chemokines - chemotactic cytokies that mediate inflammation. N. Engl. J. Med. 1998; 338: 436-445.
  37. Hasegawa M., Sato S., Takehara K. Augmented production of chemokines (MCP-1, MlP-la, and MIP-ip) in patients with systemic sclerosis: MCP-l and MIP-lcc may ne involved in the development of pulmonary fibrosis. Clin. Exp. Immunol. 1999; 117: 159-165.
  38. Lloyd A. R., Oppenheim J. J., Kelvin K. J., Taub D. D. Chemokines regulate T cell adherence to recombinant adhesion molecules and extracellular matric proteins. J. Immunol. 1996; 156: 932-938.
  39. Schall T. J., Bacon К. В. Chemokines, leukocyte trafficking, and inflammation. Curr. Opin. Immunol. 1994; 6: 865-873.
  40. Abraham D., Lupoli S., McWhlrter A. et al. Expression and function of surface antigens on scleroderma fibroblasts. Arthr. and Rheum. 1991; 34(9): 1164-1172.
  41. Needleman B. W. Increased expression of intercellular adhesion molecule 1 on the fibroblasts of scleroderma patients. Ibid. 1990; 33(12): 1847-1851.
  42. Xu S. W., Denton С. P., Dashwood M. R. et al. Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and scleroderma! fibroblasts. J. Cardiovasc. Pharmacol. 1998; 31(suppl. 1): S545-S547.
  43. Shi-Wen X., Panesar M., Vancheeswaran R. et al. Expression and shedding of intercellular adhesion molecule 1 and lymphocyte function-associated antigen 3 by normal and scleroderma fibroblasts. Effects of interferon-gamma, tumor necrosis factor alpha, and estrogen. Arthr. and Rheum. 1994: 37(100): 1689-1697.
  44. Cho M. M., Jimenez S. A., Johnson B. A. et al. In vitro cytokine modulation of intercellular adhesion molecule-1 expression on systemic sclerosis dermal fibroblasts. Pathobiology 1994; 62(2): 73-81.
  45. Majewski S., Hunzelmann N., Johnson J. P. et al. Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic scleroderma. J. Invest. Dermatol. 1991; 97(4): 667-671.
  46. Gruschwitz M. S., Hornstein Q. P., von Den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthr. and Rheum. 1995; 38(2): 184-189.
  47. Sollberg S., Peltonen J., Uitto J., Jimenez S. A. Elevated expression of beta 1 and beta 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Ibid. 1992; 35(3): 290-298.
  48. Claman H. N., Giorno R. C., Seibold J. R. Endothelial and fibroblastic activation in scleroderma. The myth of the "uninvoldesskin". Ibid. 1991; 34(12): 1495-1501.
  49. Gruschwitz M., von den Driesch P., Kellner I. et al. Expression of adhesion protein involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. J. Am. Acad. Dermatol. 1992; 27(2, pt 1): 169-177.
  50. Koch A. E., Kronfeld-Harrington L. В., Szekanecz et al. In situ expression of cytokines and cellular adhession molecules in the skin of patients with systematic sclerosis. Their role in early and late disease Pathobiology 1993; 61(5-6): 239-246.
  51. Carson С. W., Beall L. D., Hunder G. G. et al. Serum ELAM1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. J. Rheumatol. 1993; 20(5): 809-814.
  52. Sfikakis P. P., Tesar J., Baraf H. et al. Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin. Immunol. Immunopathol. 1993; 68(1): 88-92.
  53. Andersen G. N., Caidahl K., Kazzam E. et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthr. and Rheum. 2000; 43(5): 1085-1093.
  54. Kiener H., Graninger W., Machold K. et al. Increased lebels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin. Exp. Rheumatol. 1994; 12(5): 483 - 487.
  55. Sfikakis P. P., Charalambopoulos D., Vaiopoulos G., Mavrikakis M. Circulating P- and L-selectin and T-lymphocyte activation and patients with autoimmune rheumatic disease. Clin. Rheumatol. 1999; 18(1): 28-32.
  56. Ihn H., Sato S., Fujimoto M. et al. Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. Br. J. Rheumatol. 1997; 36(12): 1270-1275.
  57. Okawa-Takatsuji M., Aotsuka S., Fujinami M. et al. Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against Ul-ribonucleoprotein. Clin. Exp. Immunol. 1999; 116(1): 174-180.
  58. Straub R. H., Zeuner M., Lock G. et al. High prolactin and low dehydroepiandrosterone sulphate serum levels in patients with severe systemic sclerosis. Br. J. Rheumatol. 1997; 36(4): 426- 432.
  59. Denton С. P., Bickerstaff M. С., Shiwen X. et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Ibid. 1995; 34(11): 1048-1054.
  60. Blann A. D., Herrick A., Jayson M. I. Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Ibid. 34(9): 814-819.
  61. Sondergaard K., Stengaard-Pedersen K., Zacharie H. et al. Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin. Ibid. 1998; 37(3): 304-310.
  62. Veate D. J., Kirk G., McLaren M., Belch J. J. F. Clinical implications of soluble intercellular adhesion molecule-1 levels in systemic sclerosis. Ibid. 37(11): 1227-1228.
  63. Shahin A. A., Anwar S., Elawar A. H. et al. Circulating soluble adhesion molecules in patients with systemic sclerosis: correlation between circulating soluble vascular diastolic function Rheumatol. Int. 2000; 20(1): 21-24.
  64. Stratton R. J., Coghlan J. G., Pearson J. D. et al. Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. Quart. J. Med. 1998; 91(8): 561- 566.
  65. Thornhill M. H., Wellicome S. M.. Mahiouz D. L. et al. Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells: the contribution of vascular cell adhesion molecule-1 dependent and independent binding mechanisms. J. Immunol. 1991; 146: 592-598.
  66. Pober J. S., Gimbrone M. A., Lapierre L. A. et al. Overlapping patterns of activation of human edothelial cells by interleukin 1 tumor necrosis factor and immune interferon. Ibid. 1986; 137: 1893-1896.
  67. Iodermarco M. F., McQuillan J. J., Dean D. C. Vascular cell adhesion molecule 1: contrasting transcription control mechanisms in muscle and endothelium. Proc. Natl. Acad. Sci. USA 1993; 90: 3943-3947.
  68. Shu H. В., Agranoff A. В., Nabel E. J. et al. Differential regulation of vascular cell adhesion molecule 1 gene expression by specific NF-kB subunits in endothelial and epithelial cells. Mol. Cell. Biol. 1993; 13: 6283-6289.
  69. Gardinali M., Pozzi M. R., Bernareggi M. et al. Treatment of Raynaud's phenomenon with intravenous prostaglandin El alpha-cycloextrin improves endothelial cell injury in systemic sclerosis. J. Rheumatol. 2001; 28(4): 786-794.
  70. Szegedi A., Cz'irjak L., Unkeless J. C., Boros P. Serum cytokine and anti-Fc gamma R autoantibody measurements in patients with systemic sclerosus. Acta Dermato-Venereol. 1996; 76(1): 21-23.
  71. Kantor T. V., Friberg D., Medsger T. A. Jr. et al. Cytokine production and serum levels in systemic sclerosis. Clin. Immunol. Immunopathol. 1992; 65(3): 278-285.
  72. Kawaguchi Y. IL-l alpha gene expression and protein priduction by fibroblasts from patients with systemic sclerosis. Clin. Exp. Immunol. 1994; 97(3): 445-450.
  73. Carvalho D., Savage С. О., Black С. М., Pearson J. D. IgG antiendothelial cell antibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J. Clin. Invest. 1996; 97(1): 111-119.
  74. Kurosawa K., Hirose K., Sano N. et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthr. and Rheum. 2000; 43(11): 2455-2463.
  75. Pittoni V., Litta A., Squilloni E. et al. Soluble intercellular adhesion molecule-1 in a geographical cluster of scleroderma. Br. J. Rheumatol. 1994; 33(12): 1193-1194.
  76. Schlegel P. G., Vaysburd M., Chen Y. et al. Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibilaty barriers. J. Immunol. 1995; 155: 3856-3865.
  77. Mittag M., Beckheinrich P., Haustein U. F. Systemic sclerosisrelated Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Dermato-Venereol. 2001; 81(4): 294- 297.
  78. Inaoki M., Sato S., Shimada Y., Takehara K. Elevated serum levels of soluble L-selectin in patients with systemic sclerosis declined after intravenous injection of lipoprostagladin El. J. Dermatol. 2001; 25(1): 78-82.
  79. Denton С. P., Howell K., Stratton R. J., Black С. М. Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study. Clin. Exp. Rheumatol. 2000; 18(4): 499-502.
  80. Dziadzio M., Denton C. P., Smith R. et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallelgroup, controlled trial. Arthr. and Rheum. 1999; 42(12): 26462655.

Copyright (c) 2003 Alekperov R.Т., Timchenko A.V., Nasonov E.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies